You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Access to new cancer medicines in Australia: dispelling the myths and informing a public debate
|
|---|---|
| Published in |
Journal of Pharmaceutical Policy and Practice, April 2016
|
| DOI | 10.1186/s40545-016-0062-x |
| Pubmed ID | |
| Authors |
Agnes Vitry, Barbara Mintzes, Wendy Lipworth |
| Abstract |
Despite the high level of spending on cancer medicines in Australia, consumer organisations and the pharmaceutical industry often make claims of delayed or lack of access to new cancer medicines-claims that are frequently supported by prominent coverage in the Australian media. These claims, while morally and psychologically compelling, tend to ignore the complexity of medicines funding decisions. In this commentary we summarise the current situation regarding the registration and funding of cancer medicines in Australia, elucidate the main challenges associated with access to cancer medicines in the Australian context, and describe some of the steps that have been taken to address these challenges. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 50% |
| United States | 1 | 25% |
| Canada | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 2 | 50% |
| Members of the public | 1 | 25% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 26 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 23% |
| Student > Master | 5 | 19% |
| Student > Doctoral Student | 3 | 12% |
| Student > Postgraduate | 3 | 12% |
| Student > Ph. D. Student | 2 | 8% |
| Other | 3 | 12% |
| Unknown | 4 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 38% |
| Economics, Econometrics and Finance | 4 | 15% |
| Social Sciences | 2 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 8% |
| Biochemistry, Genetics and Molecular Biology | 1 | 4% |
| Other | 3 | 12% |
| Unknown | 4 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 August 2022.
All research outputs
#4,446,124
of 24,520,187 outputs
Outputs from Journal of Pharmaceutical Policy and Practice
#116
of 452 outputs
Outputs of similar age
#65,460
of 305,997 outputs
Outputs of similar age from Journal of Pharmaceutical Policy and Practice
#6
of 11 outputs
Altmetric has tracked 24,520,187 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 452 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.4. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 305,997 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.